Luke Evnin, Director at Werewolf Therapeutics, Inc. (HOWL), sold 141,106 shares at $0.48 ($66K) on 2026-05-27, disclosed to the SEC on 2026-05-29.
Scheduled sale ($66k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.48 | 80,852 | $39K | 58.6% |
| 2 | $0.46 | 27,698 | $13K | 19.2% |
| 3 | $0.45 | 32,556 | $15K | 22.1% |
| Total | $0.47 avg | 141,106 | $66K | 100% |
| Filing → |
| HOWL | SELL | 2026-06-10 | $28K | — | Filing → |
| HOWL | SELL | 2026-06-08 | $43K | — | Filing → |
| HOWL | SELL | 2026-06-03 | $64K | — | Filing → |